Lowe, Eric
Mossé, Yael P.
Funding for this research was provided by:
Pfizer
Article History
Received: 5 October 2023
Accepted: 25 March 2024
First Online: 27 April 2024
Conflict of Interest
: Eric Lowe participated on the data safety monitoring board for the European study of ALK inhibitors. Yael P Mossé reports consulting fees from Pfizer, served as a principal investigator for the COG ADVL0912 trial, received crizotinib and lorlatinib via an MTA for preclinical work in the laboratory, and is a member of the ASCO TAPUR DSMB.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.